68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study
Recruiting
Observational Study
Solid Cancers
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This project aims to monitor the innocuity/safety profile of cyclotron-produced \[68Ga\]-PSMA-617 PET imaging in PSMA-expressing cancers. It is a single-site, pragmatic, non-randomized and open-label study, with no control group. Although prostate cancers constitute the usual recommended population for this PET modality, recent evidences suggest that most solid tumors express substantial amount of…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Clinical requisition for a 68Ga-PSMA-617 PET/CT signed by a referring doctor;
2. Patients with suspected, proven or prior tumor expressing PSMA;
3. Informed consent by patient.
Exclusion Criteria:
1. Patient refusal to participate;
2. Prior severe anaphylactic reaction to 6…
Contacts